Obinutuzumab v léčbě pacientky s Waldenströmovou makroglobulinémií netolerující rituximab - popis případu.

Obinutuzumab is a new anti-CD20 monoclonal antibody predominantly used in the treatment of patients with chronic lymphocytic leukaemia and follicular lymphoma. In our case report, we describe successful treatment using obinutuzumab in a patient with Waldenström macroglobulinemia. This therapy was used as 4th line-treatment and led to complete bio-chemical and clinical response of Waldenström macroglobulinemia. Obitunuzumab could thus be useful option even in such a rare disease. [ABSTRACT FROM AUTHOR]